Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan.
Akiyama
T
T
Department of Urology, Sakai Hospital, Kinki University, Sakai City, Osaka, Japan. akiyama@sakai.med.kindai.ac.jp
Okazaki
H
H
Takahashi
K
K
Hasegawa
A
A
Tanabe
K
K
Uchida
K
K
Takahara
S
S
Toma
H
H
D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D007239:Infections / Q000453:epidemiology; D007564:Japan; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D019520:Living Donors; D011183:Postoperative Complications / Q000453:epidemiology; D012263:Ribonucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D016559:Tacrolimus